- Home
- AXP vs NVO Comparison
AXP vs NVO Comparison
Compare AXP & NVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | AXP | NVO |
|---|---|---|
| Founded | 1850 | 1923 |
| Country | United States | Denmark |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 255.1B | 212.7B |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | AXP | NVO |
|---|---|---|
| Price | $383.83 | $52.46 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 22 | 11 |
| Target Price | ★ $329.95 | $54.25 |
| AVG Volume (30 Days) | 2.5M | ★ 16.7M |
| Earning Date | 01-30-2026 | 02-04-2026 |
| Dividend Yield | 0.86% | ★ 2.38% |
| EPS Growth | 9.59 | ★ 10.06 |
| EPS | ★ 14.88 | 3.67 |
| Revenue | ★ $65,294,000,000.00 | $49,580,393,058.00 |
| Revenue This Year | $19.86 | $7.77 |
| Revenue Next Year | $8.91 | $1.86 |
| P/E Ratio | $25.69 | ★ $14.08 |
| Revenue Growth | 10.22 | ★ 16.64 |
| 52 Week Low | $220.43 | $43.08 |
| 52 Week High | $387.49 | $93.80 |
Technical Indicators
Market Signals| Indicator | AXP | NVO |
|---|---|---|
| Relative Strength Index (RSI) | 63.82 | 62.78 |
| Support Level | $372.77 | $47.59 |
| Resistance Level | $387.49 | $48.80 |
| Average True Range (ATR) | 7.27 | 1.19 |
| MACD | 0.23 | 0.49 |
| Stochastic Oscillator | 83.22 | 85.50 |
Price Performance
Historical ComparisonAbout AXP American Express Company
American Express is a global financial institution, operating in about 130 countries, that provides consumers and businesses charge and credit card payment products. The company also operates a highly profitable merchant payment network. It operates in four segments: US consumer services, US commercial services, international card services, and global merchant and network services. In addition to payment products, the company's commercial business offers expense management tools, consulting services, and business loans.
About NVO Novo Nordisk A/S
With roughly one-third of the global branded diabetes treatment market, Novo Nordisk is the leading provider of diabetes care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments such as GLP-1 therapy, oral antidiabetic agents, and obesity treatments. Novo also has a biopharmaceutical segment (contributing less than 10% of revenue) that specializes in protein therapies for hemophilia and other disorders.